Emerald Acquisition’s Eledon Pharmaceuticals ELDN Stock Holding History

Emerald Acquisition’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$150K	Buy	+603	New	+$221K	﹤0.01%	2748

Other funds holding ELDN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Acquisition's ELDN Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Eledon Pharmaceuticals (ELDN) in Q3 2016: 603 shares worth $150K. The stake represents ﹤0.01% of the portfolio and ranks #2748 among its holdings.

44 funds tracked by Wall St. Rank hold ELDN as of Q3 2016.

Emerald Acquisition held 603 shares of Eledon Pharmaceuticals worth $150K as of Q3 2016.
Eledon Pharmaceuticals was a new Emerald Acquisition position in Q3 2016.
Eledon Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2748 holding.
44 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.